Balazs Halmos, Associate Director for Clinical Science at Montefiore Einstein Cancer Center and Professor of Medicine
Professor of Medicine at Montefiore Health System, shared a post on X about a paper by Margaux Wooster et al. published in JNCI:
“Let me introduce you to the typical patient who is able to meet all 40 or so cancer clinical trial eligibility criteria of a usual sponsored trial.
And allow me to bring to your attention this great paper by Benjamin Herzberg (open access), highlighting the very restrictive nature of case-in-point K-Ras focused trials with actionable items for improvement, so not only Superman/Superwoman could have access to exciting novel drugs!”
Isabel Preeshagul, Thoracic Medical Oncologist at Memorial Sloan Kettering Cancer Center, shared this post, adding:
“Here it is clear as day.
Strict inclusion-exclusion criteria need to be reexamined. We are limiting options for our patients!
Thank you for this great work.”
Title: The impact of eligibility criteria on KRASG12C inhibitor trials in patients with NSCLC
Authors: Margaux Wooster, Michael May, Prashasti Agrawal, Jonathan Lee, Benjamin May, Xin Ma, Stephanie Bogdan, Catherine A Shu, Brian S Henick, Anjali Saqi, Mahesh Mansukhani, Gregory Riely, Dawn L Hershman, Christine Garcia, Kathryn C Arbour, and Benjamin O Herzberg
You can read the Full Article in JNCI: Journal of the National Cancer Institute.
More posts featuring Balazs Halmos.
